bioRxiv / medRxiv
open access
GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression
ImportanceRandomised-controlled trials (RCTs) suggest glucagon-like-peptide-1 receptor agonists (GLP-1RAs) reduce the risk of stroke in type 2 diabetes (T2DM); however, the mechanisms remain unclear. If benefits were driven principally by blood pressure (BP) lowering, similar effects on cognitive im
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Psychology of GLP-1 Receptor Agonists: Evidence for Distinct Effects on Reward, Interoception and Cognition#1360396
- Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health#808149
- GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.#631018
- GLP-1 receptor agonist use is associated with shorter survival in patients with amyotrophic lateral sclerosis and diabetes mellitus#1181784
- An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders#258766
Record · ID 1394077
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive